{
  "slug": "amyris-historicrestructuring",
  "name": "Amyris Historicrestructuring (Amyris Inc.)",
  "description": "Amyris Inc. is a synthetic biology company that transitioned from consumer goods back to its core technology platform following a major corporate restructuring in 2023-2024. The term 'Historicrestructuring' refers to its Chapter 11 reorganization process where it divested several consumer brands to focus on R&D and business-to-business ingredient production.",
  "url": "https://optimly.ai/brand/amyris-historicrestructuring",
  "logoUrl": "",
  "baiScore": 15,
  "archetype": "Phantom",
  "category": "Biotechnology",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "inboundCompetitors": [
    {
      "slug": "genomatica-geno",
      "name": "Genomatica (Geno)"
    }
  ],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-04-10T18:12:34.038+00:00",
  "verifiedVitals": {
    "website": "amyris.com (Corporate)",
    "founded": "2003 (Original Amyris)",
    "headquarters": "Emeryville, California, USA",
    "pricing_model": "Enterprise/Custom (B2B partnerships)",
    "core_products": "Fermentation-based ingredient manufacturing, Synthetic Biology R&D, Lab-to-Market technology platform.",
    "key_differentiator": "A uniquely scaled fermentation platform that has successfully commercialized multiple bio-identical molecules, despite financial setbacks.",
    "target_markets": "Health & Wellness, Beauty, Flavor & Fragrance, Pharmaceuticals.",
    "employee_count": "Not publicly available",
    "funding_stage": "Not publicly available",
    "subcategory": "Synthetic Biology & Specialty Ingredients"
  },
  "intentTags": {
    "problemIntents": [
      "Internal Finance Teams: Companies in distress may attempt to manage liquidity and creditor negotiations using internal finance teams and spreadsheets.",
      "Management Consulting: Hiring traditional management consulting firms to provide strategic direction during a downturn without formal legal restructuring.",
      "General Legal Counsel: Relying on generic legal counsel who do not specialize in Chapter 11 or insolvency."
    ],
    "solutionIntents": [
      "synthetic biology companies 2024",
      "sustainable ingredient manufacturing partners",
      "Amyris current operations post-bankruptcy",
      "who bought Amyris brands",
      "Amyris bio-tech restructuring details"
    ],
    "evaluationIntents": []
  },
  "timestamp": 1776207218654
}